EA201790341A1 - Анти-ск8 антитела для применения в лечении рака - Google Patents

Анти-ск8 антитела для применения в лечении рака

Info

Publication number
EA201790341A1
EA201790341A1 EA201790341A EA201790341A EA201790341A1 EA 201790341 A1 EA201790341 A1 EA 201790341A1 EA 201790341 A EA201790341 A EA 201790341A EA 201790341 A EA201790341 A EA 201790341A EA 201790341 A1 EA201790341 A1 EA 201790341A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibody
relates
present
seq
antibody fragment
Prior art date
Application number
EA201790341A
Other languages
English (en)
Other versions
EA036368B1 (ru
Inventor
Мари Александра Альбаре
Жан-Жак Диаз
Ишем Клод Мертани
Жан-Кристоф Сорен
Клодин Вермо-Десроше
Борис Вюйермоз
Original Assignee
Интернэшнл - Драг - Дивелопмент - Байотек
Юниверсите Клод Бернар Лион 1
Оспис Сивиль Де Лион
Сантр Насьональ Де Ля Решерш Сьентифик (Снрс)
Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль (Инсерм)
Сантр Лион Берар
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Интернэшнл - Драг - Дивелопмент - Байотек, Юниверсите Клод Бернар Лион 1, Оспис Сивиль Де Лион, Сантр Насьональ Де Ля Решерш Сьентифик (Снрс), Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль (Инсерм), Сантр Лион Берар filed Critical Интернэшнл - Драг - Дивелопмент - Байотек
Publication of EA201790341A1 publication Critical patent/EA201790341A1/ru
Publication of EA036368B1 publication Critical patent/EA036368B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4741—Keratin; Cytokeratin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2410/00—Assays, e.g. immunoassays or enzyme assays, involving peptides of less than 20 animo acids

Abstract

Настоящее изобретение относится к антителу или фрагменту антитела, или гуманизированному антителу или фрагменту антитела, специфически связывающемуся с пептидом, имеющим аминокислотную последовательность, представленную в SEQ ID No. 29. Также, настоящее изобретение относится к антителу или фрагменту антитела по любому из предшествующих пунктов для его применения в лечении опухолей, клетки которых экспрессируют на своей поверхности белок СК8, в частности пептид с последовательностью в соответствии с SEQ ID No. 29. Также, настоящее изобретение относится к антигенному пептиду человеческого СК8, состоящему из полипептида, имеющего от 8 до 16 аминокислот и содержащего последовательность, представленную в SEQ ID No. 29, и применению указанного антигенного пептида человеческого СК8 в качестве терапевтического агента. Также, настоящее изобретение относится к фармацевтической композиции или набору для диагностики, содержащему антитело или фрагмент антитела. Также, настоящее изобретение относится к набору, в частности, предназначенному для применения в обнаружении рака, включающему контейнер, содержащий молекулу, специфически связывающуюся с антигенным пептидом человеческого СК8, состоящим из полипептида, имеющего от 8 до 16 аминокислот и содержащего последовательность, представленную в SEQ ID No. 29.
EA201790341A 2014-08-08 2015-08-10 Анти-ck8 антитела для применения в лечении рака EA036368B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1457704A FR3024731B1 (fr) 2014-08-08 2014-08-08 Anticorps anti-ck8 pour utilisation dans le traitement des cancers
PCT/EP2015/068400 WO2016020553A1 (en) 2014-08-08 2015-08-10 Anti-ck8 antibodies for use in the treatment of cancers

Publications (2)

Publication Number Publication Date
EA201790341A1 true EA201790341A1 (ru) 2017-06-30
EA036368B1 EA036368B1 (ru) 2020-10-30

Family

ID=51987264

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790341A EA036368B1 (ru) 2014-08-08 2015-08-10 Анти-ck8 антитела для применения в лечении рака

Country Status (10)

Country Link
US (1) US10533046B2 (ru)
EP (1) EP3189078B1 (ru)
JP (1) JP6689847B2 (ru)
KR (1) KR102478986B1 (ru)
CN (1) CN107001452B (ru)
CA (1) CA2959671C (ru)
EA (1) EA036368B1 (ru)
FR (1) FR3024731B1 (ru)
IL (1) IL250507B (ru)
WO (1) WO2016020553A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3024731B1 (fr) * 2014-08-08 2019-06-14 International - Drug - Development - Biotech Anticorps anti-ck8 pour utilisation dans le traitement des cancers
EP3444272A1 (en) 2017-08-17 2019-02-20 International-Drug-Development-Biotech Treatment of ck8 positive cancers in relation with k-ras gene status
CN111018984B (zh) * 2019-11-26 2021-09-21 山东立菲生物产业有限公司 抗ck8单克隆抗体及其应用
CN113234156B (zh) * 2021-05-25 2022-05-03 宁波赛珀生物技术有限公司 一种抗肌红蛋白的抗体及其制备方法和应用
CN114874320B (zh) * 2022-06-28 2023-08-04 王玉 含有外泌体的药物组合物及其制备方法
CN116478285B (zh) * 2023-01-20 2024-03-12 上海大格生物科技有限公司 诊断性小鼠源化抗人ck抗体及其制备方法和应用
CN117430707B (zh) * 2023-10-25 2024-04-19 重庆天科雅生物科技有限公司 一种cik细胞的制备方法及其在治疗癌症中的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168181B2 (en) * 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
FR2945952B1 (fr) 2009-05-27 2013-10-04 Univ Claude Bernard Lyon Anticorps anti-ck8 pour utilisation comme medicament.
EP2602265A1 (en) * 2011-12-07 2013-06-12 Centre National de la Recherche Scientifique (CNRS) Antibodies anti-sPLA2-X and uses thereof
FR3024731B1 (fr) * 2014-08-08 2019-06-14 International - Drug - Development - Biotech Anticorps anti-ck8 pour utilisation dans le traitement des cancers

Also Published As

Publication number Publication date
CA2959671C (en) 2023-10-03
KR102478986B1 (ko) 2022-12-16
EP3189078A1 (en) 2017-07-12
US20180237508A1 (en) 2018-08-23
FR3024731A1 (fr) 2016-02-12
CN107001452B (zh) 2021-01-08
IL250507B (en) 2021-10-31
WO2016020553A1 (en) 2016-02-11
KR20170082495A (ko) 2017-07-14
JP6689847B2 (ja) 2020-05-27
EA036368B1 (ru) 2020-10-30
CA2959671A1 (en) 2016-02-11
JP2017534661A (ja) 2017-11-24
EP3189078B1 (en) 2020-11-04
CN107001452A (zh) 2017-08-01
FR3024731B1 (fr) 2019-06-14
IL250507A0 (en) 2017-03-30
US10533046B2 (en) 2020-01-14

Similar Documents

Publication Publication Date Title
EA201790341A1 (ru) Анти-ск8 антитела для применения в лечении рака
CY1121900T1 (el) Ανθρωποποιημενο αντισωμα αντι καλλικρεϊνης-2
EA202091710A1 (ru) Антитела против cd73 и способы их применения
CL2019001926A1 (es) Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017).
EA201991099A1 (ru) Антитела против cd73 и их применение
EA201891435A1 (ru) Гуманизированные моноклональные антитела, моноклональные антитела мыши или химерные моноклональные антитела против cd47
EA201791666A1 (ru) Антитела к cd3, антитела к cd123 и биспецифические антитела, которые специфически связываются с cd3 и/или cd123
EA201792221A1 (ru) Антитела против сортилина и способы их применения
PH12019500596A1 (en) Recombinant binding proteins and their use
MX2018009011A (es) Anticuerpos anti receptor 1 transmembrana de tirosina-proteina cinasa (ror1) y usos de los mismos.
BR112017003194A2 (pt) anticorpo ou fragmento de ligação ao antígeno do mesmo, composição, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, vacina, vaso ou dispositivo de injeção, e, métodos para antagonizar lag3 em um paciente humano que necessita do mesmo, para tratamento de um câncer em um indivíduo para administrar o anticorpo, o fragmento, a composição, o polipeptídeo, a vacina, o vetor ou o polinucleotídeo de ligação ao antígeno a um indivíduo, para produção de um anticorpo ou de um fragmento de ligação ao antígeno do mesmo ou polipeptídeo e para detectar a presença de um peptídeo lag3 ou de um fragmento do mesmo em uma amostra.
EA201990321A1 (ru) Биспецифические антителоподобные связывающие белки, которые специфически связываются с cd3 и cd123
MX360208B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX360211B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX363136B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
PH12019500609A1 (en) Cd123 binding proteins and related compositions and methods
NZ713461A (en) Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
WO2017060322A3 (en) Ptefb-inhibitor-adc
MX2016004579A (es) Proteinas de union del miembro 1 de la familia de transmembrana 4 l-seis (tm4sf1) y metodos de uso de las mismas.
CY1121734T1 (el) ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ
MX2020002921A (es) Anticuerpos para claudin6 y métodos para tratar el cáncer.
CY1118046T1 (el) Πρωτεϊνες δεσμευσης με αντιγονο ειδικες για το συστατικο ρ αμυλοειδους ορου
EA201790816A1 (ru) Антитела, которые связываются с ccr6, и варианты применения указанных антител
MX2021010281A (es) Proteinas de enlace a antigenos que se enlazan al bcma.
EA201892313A1 (ru) Гуманизированные антитела против clever-1 и их применение

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM